Form 8-K - Current report:
SEC Accession No. 0001104659-21-149603
Filing Date
2021-12-14
Accepted
2021-12-14 17:09:28
Documents
14
Period of Report
2021-12-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2135051d1_8k.htm   iXBRL 8-K 31063
2 EXHIBIT 5.1 tm2135051d1_ex5-1.htm EX-5.1 34737
6 GRAPHIC image_001.jpg GRAPHIC 1657
  Complete submission text file 0001104659-21-149603.txt   252100

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eyen-20211214.xsd EX-101.SCH 3034
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eyen-20211214_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eyen-20211214_pre.xml EX-101.PRE 22365
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2135051d1_8k_htm.xml XML 3700
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 211491825
SIC: 2834 Pharmaceutical Preparations